<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40808656</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4636</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Arteriosclerosis, thrombosis, and vascular biology</Title><ISOAbbreviation>Arterioscler Thromb Vasc Biol</ISOAbbreviation></Journal><ArticleTitle>Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes.</ArticleTitle><Pagination><StartPage>1935</StartPage><EndPage>1944</EndPage><MedlinePgn>1935-1944</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.125.322347</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">OxPL-apoB (oxidized phospholipids [OxPL] on apoB-100), which include OxPL present on Lp(a) (lipoprotein[a]), are associated with higher cardiovascular risk. Experimental studies suggest that OxPL may influence platelet function.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This observational study assessed the association of OxPL-apoB with intrinsic and on&#x2011;clopidogrel platelet reactivity and long-term cardiovascular events in patients undergoing coronary angiography with or without percutaneous coronary intervention in 2040 patients in the EXCELSIOR trial (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate). The association of OxPL-apoB to expression of CD62P, CD41, or PAC-1 levels and intrinsic and on-clopidogrel platelet reactivity to collagen and ADP was determined. The relationship of OxPL-apoB and Lp(a) to myocardial infarction-free survival and all-cause mortality at a median of 7 years was assessed using Cox regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Elevated levels of OxPL-apoB were associated with the severity of coronary obstruction, and higher prevalence of prior myocardial infarction, percutaneous coronary intervention, and coronary artery bypass graft surgery. No significant associations were present between OxPL-apoB and intrinsic or on-clopidogrel platelet reactivity or activation of platelet receptors. Analyzed individually in separate multivariable models, both OxPL-apoB (hazard ratio, 1.022 [95% CI, 1.005-1.040]; <i>P</i>=0.010) and Lp(a) (hazard ratio, 1.002 [95% CI, 1.000-1.005]; <i>P</i>=0.032) were associated with worse myocardial infarction-free survival. However, in a joint multivariable model analyzed together, neither OxPL-apoB nor Lp(a) was significant. The optimal cut point for myocardial infarction-free survival for OxPL-apoB was 8 nmol/L (hazard ratio, 1.391 [95% CI, 1.086-1.780]; <i>P</i>=0.009) and for Lp(a) 30 mg/dL (hazard ratio, 1.261 [95% CI, 1.012-1.570]; <i>P</i>=0.038).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In patients undergoing coronary angiography with or without percutaneous coronary intervention, OxPL-apoB was not associated with intrinsic and on-clopidogrel platelet reactivity mediated by collagen or ADP. The association of OxPL-apoB and Lp(a) suggests that the accumulation of OxPL on Lp(a) may be a key determinant of long-term cardiovascular outcomes.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="UNASSIGNED">URL: https://www.clinicaltrials.gov; Unique identifier: NCT00457236.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tsimikas</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9834-9494</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego (S.T., X.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kille</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6431-519X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaier</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0837-6945</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biometry and Statistics (K.K.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfc;hrenberg</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7675-7120</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Kilian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valina</LastName><ForeName>Christian M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego (S.T., X.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leibundgut</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0122-5397</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, University Hospital of Basel, Switzerland (G.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Franz-Josef</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0002-0921-8351</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7542-1956</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochholzer</LastName><ForeName>Willibald</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Intensive Care Medicine, Klinikum Wuerzburg Mitte, Germany (W.H.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00457236</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL159156</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL170224</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA><NlmUniqueID>9505803</NlmUniqueID><ISSNLinking>1079-5642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053299">Apolipoprotein B-100</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017270">Lipoprotein(a)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053299" MajorTopicYN="Y">Apolipoprotein B-100</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015539" MajorTopicYN="Y">Platelet Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="N">Clopidogrel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="Y">Phospholipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="Y">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017270" MajorTopicYN="N">Lipoprotein(a)</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">clopidogrel</Keyword><Keyword MajorTopicYN="N">lipoproteins</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword></KeywordList><CoiStatement>S. Tsimikas is a co-inventor and has received royalties from patents owned by the University of California-San Diego. S. Tsimikas is a cofounder of and has an equity interest in Oxitope and Kleanthi Diagnostics and has a dual appointment at the University of California San Diego and Ionis Pharmaceuticals. A. Kille reports speaker honoraria from Sysmex. T. N&#xfc;hrenberg is an employee of Novartis as of October 1, 2021. W. Hochholzer received consultancy fees or speaker honoraria from Daiichi Sankyo, Novartis, and Bayer. F.-J. Neumann reports that his institution has received research grants, consultancy fees, and speaker honoraria from Daiichi Sankyo, Astra Zeneca, Sanofi-Aventis, Bayer, The Medicines Company, Bristol, Novartis, Roche, Boston Scientific, Biotronik, Medtronic, Edwards, and Ferrer. W. Hochholzer received consultancy honoraria from Daiichi Sankyo, The Medicines Company, and Ferrer and reports speaker honoraria from AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, and feo GmbH as well as research grants paid to his former institution from German Heart Foundation, Novartis, and Sysmex. The other authors report no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40808656</ArticleId><ArticleId IdType="mid">NIHMS2100963</ArticleId><ArticleId IdType="pmc">PMC12421647</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.125.322347</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>